公开(公告)号：US20200331909A1

公开(公告)日：2020-10-22

申请号：US16849329

申请日：2020-04-15

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Douglas Carl Behenna ,  Kimberly O. Cameron ,  Ping Chen ,  John M. Curto ,  Kevin Daniel Freeman-Cook ,  Mehran Jalaie ,  Robert Steven Kania ,  Yajing Lian ,  Sajiv Krishnan Nair ,  Cynthia Louise Palmer ,  Martin Youngjin Pettersson ,  Eugene Yuanjin Rui ,  Matthew Sammons ,  Qingyi Yang ,  Liying Zhang

IPC: C07D471/04 ,  A61P9/12

Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

公开(公告)号：US11203594B2

公开(公告)日：2021-12-21

申请号：US16849329

申请日：2020-04-15

Applicant: Pfizer Inc.

Inventor： Samit Kumar Bhattacharya ,  Douglas Carl Behenna ,  Kimberly O. Cameron ,  Ping Chen ,  John M. Curto ,  Kevin Daniel Freeman-Cook ,  Mehran Jalaie ,  Robert Steven Kania ,  Yajing Lian ,  Sajiv Krishnan Nair ,  Cynthia Louise Palmer ,  Martin Youngjin Pettersson ,  Eugene Yuanjin Rui ,  Matthew Sammons ,  Qingyi Yang ,  Liying Zhang

IPC: C07D471/04 ,  A61P9/12

Abstract: This invention relates to compounds of general Formula I in which A, R1, R2, R3 and R4 are as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

公开(公告)号：US20140080756A1

公开(公告)日：2014-03-20

申请号：US14083275

申请日：2013-11-18

Applicant: Pfizer Inc.

Inventor： Samit K. Bhattacharya ,  Kimberly O. Cameron ,  Dilinie P. Fernando ,  Kim F. McClure ,  Daniel W. Kung ,  Allyn T. Londregan ,  Suvi T.M. Orr

IPC: C07D471/10 ,  A61K31/506 ,  A61K31/53 ,  A61K31/435 ,  A61K31/497 ,  C07D491/056 ,  C07D513/04 ,  A61K45/06

CPC classification number: C07D471/10 ,  A61K31/435 ,  A61K31/497 ,  A61K31/506 ,  A61K31/53 ,  A61K45/06 ,  C07D491/056 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention provides a compound of Formula (I) a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

Abstract translation: 本发明提供了其作为Ghrelin拮抗剂或反向激动剂的其中R 1，R 2，R a，L，Z，Z 1和Z 2如本文所定义的药用盐的式（I）化合物; 其药物组合物; 以及治疗由Ghrelin受体的拮抗作用介导的疾病，病症或病症的方法。